Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Astellas/Pfizer’s Xtandi Given FDA’s Priority Review for Hormone-Sensitive Prostate Cancer
Astellas Pharma and its partner Pfizer said on August 21 that the US FDA has granted a priority review status for Xtandi (enzalutamide) for the treatment of men with metastatic hormone-sensitive prostate cancer (mHSPC), with the agency’s decision expected by…
To read the full story
Related Article
- Xtandi Filed for Hormone-Sensitive Prostate Cancer in Japan
July 31, 2019
- EMA Accepts Xtandi for Review in Hormone-Sensitive Prostate Cancer
July 25, 2019
- Astellas/Pfizer Unveil Positive Xtandi Data for Hormone-Sensitive Prostate Cancer
February 13, 2019
- Xtandi Smashes Primary Goal in Patients with mHSPC in PIII Trial
December 25, 2018
BUSINESS
- Hisamitsu Starts Promotion of Yaz AGs under Bayer Alliance
March 11, 2026
- Seagen ADC Patent Dispute Ends with Daiichi Sankyo Victory
March 11, 2026
- Seikagaku Re-Files Herniated Disk Drug with US FDA
March 11, 2026
- Lotte to Step Up CVC Investments to Drive CDMO Synergies
March 10, 2026
- Ipsen to Withdraw Tazverik Overseas over Secondary Cancer Risk
March 10, 2026
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…